Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second...
Barchart Research What to Expect from LRMR Earnings LRMR Generated May 12, 2026 Current Price $4.13 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.86% Will Larimar Therapeutics Finally...
Barchart Research What to Expect from LRMR Earnings LRMR Generated May 5, 2026 Current Price $4.01 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.86% Larimar Therapeutics: The Safety Narrative...
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,...
Barchart Research What to Expect from LRMR Earnings LRMR Generated April 28, 2026 Current Price $4.40 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.86% Larimar Therapeutics: Will Tomorrow's...
Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study Continued alignment...
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,...
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...